TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06440746: A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase 2/3 Study of Efficacy and Safety of Olokizumab in Subjects With Progressive Fibrosing Interstitial Lung Diseases

Sponsor: R-Pharm International, LLC · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 138 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,713,768

Rescue Site Savings

+$1,782,176

Unlock Full NCT06440746 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06440746 Rescue Dossier →